The Department of Health in Abu Dhabi granted clearance for the testing of NEO212, an oral conjugate designed to treat aggressive brain tumors. This international expansion arrives after the company finalized its Phase 1 dose escalation, identifying 610 mg as the optimal dosage for the upcoming study.
In section Market Quotes
NeOnc Advances Brain Cancer Drug Trials to UAE
A 13% surge in NeOnc Technologies stock followed news that Abu Dhabi health officials have greenlit Phase 2 clinical trials for the company’s experimental brain cancer drug. The $5.09 share price reflects investor optimism as the firm expands its testing footprint beyond ongoing U.S. regulatory discussions.
Despite the regulatory nod, the path to patient enrollment remains subject to further administrative hurdles. NeOnc must secure approval from an institutional review board and finalize updates to its study protocol, investigator brochures, and product labeling. The company emphasized that this authorization is strictly limited to clinical research and does not constitute marketing approval.
Comments (0)
No comments yet. Be the first!